We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s Coronavirus Treatment Acceleration Program is gearing up for a second wave of potential COVID-19 treatments and vaccines as the search for effective products gains momentum. Read More
Alexion Pharmaceuticals plans to initiate a global phase 3 clinical trial to evaluate Ultomiris (ravulizumab-cwvz) in hospitalized patients with severe COVID-19. Read More
Novartis said it will begin enrollment in the next few weeks for a phase 3 clinical trial to evaluate hydroxychloroquine for treatment of hospitalized COVID-19 patients. The trial will include more than 440 participants at more than a dozen U.S. sites. Read More
Sponsors that choose to conduct remote trial monitoring during the COVID-19 crisis should focus on the most critical site documentation and source data and ensure the security of the data by creating a secure electronic viewing portal or using a sponsor-controlled electronic system or cloud-based repository, says an updated guidance the FDA released last week. Read More
Sixteen drugmakers have signed on for a major initiative by the National Institutes of Health to speed the development of COVID-19 therapies and vaccines. Read More